Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
ELCC 2019
The 9th European Lung Cancer Conference
Geneva, Switzerland - 10 Apr - 13 Apr 2019
Presentation Date(s):- 10 Apr - 13 Apr 2019
- Total Presentations: 489
-
+
Challenges in clinical oncology: YO case discussions
- Type: Educational session
- Presentations: 9
- Coordinates: 4/11/2019, 09:00 - 10:30, Room C
-
+
Mentor guided discussion
09:40 - 09:55 | Presenter: Suresh Senan
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Current role and future of thoracic radiotherapy
- Type: Specialty session
- Presentations: 6
- Coordinates: 4/11/2019, 11:00 - 12:30, Room C
-
+
Synchronous and metachronous primary tumours
12:00 - 12:20 | Presenter: Suresh Senan
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Lunch & Poster Display session
- Type: Poster Display session
- Presentations: 170
- Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
-
+
58P - Evaluation of a care path for patients with lung tumors and co-existing interstitial lung disease
12:30 - 12:30 | Presenter: Merle Ilona Ronden-Kianoush
- Abstract
Loading... -
+
67TiP - ADRIATIC: A phase III trial of durvalumab ± tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer
12:30 - 12:30 | Presenter: Suresh Senan
- Abstract
Loading... -
+
73P - Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries
12:30 - 12:30 | Presenter: Ronald Damhuis
- Abstract
Loading... -
+
185TiP - RATIONALE 001: Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Presenter: Luis Paz-Ares
- Abstract
Loading...
